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A B S T R A C T
Purpose: Polybrominated diphenyl ethers (PBDEs) are among the most persistent and pervasive global en-
vironmental contaminants. Their toxic and endocrine-disrupting properties have made them a focus of concern
for breast cancer. Our objective was to evaluate the risk of breast cancer associated with serum PBDE levels in a
case-control study nested within the California Teachers Study.
Methods: Participants were 902 women with invasive breast cancer (cases) and 936 with no such diagnosis
(controls) who provided 10mL of blood and were interviewed between 2011 and 2015. Blood samples were
collected from cases an average of 35months after diagnosis. PBDEs were measured in serum using automated
solid phase extraction and gas chromatography/high resolution mass spectrometry. Statistical analyses were
restricted to the three congeners with detection frequencies ≥75%: 2,2′,4,4′-tetrabromodiphenyl ether (BDE-
47), 2,2′,4,4′,6-pentabromodiphenyl ether (BDE-100), and 2,2′,4,4′,5,5′-hexabromodiphenyl ether (BDE-153).
Unconditional logistic regression was used to estimate multivariable-adjusted odds ratios (ORs) and their 95%
confidence intervals (CI) for each BDE congener, adjusting for serum lipids and other potential confounders.
Results: The OR for each of the three BDE congeners was close to unity with a CI that included one. Analyses
stratified by menopausal status, tumor hormone responsiveness, BMI, and changes in body weight yielded si-
milarly null results.
Conclusions: Our findings provide no evidence that serum levels of BDE-47, BDE-100 or BDE-153 are associated
with breast cancer risk. These results should be interpreted in the context of study limitations which include the
reliance on PBDE measurements that may not represent pre-diagnostic, early-life or chronic exposures and a lack
of information on genetic polymorphisms and other factors which may affect endogenous estrogen levels.
1. Introduction
Breast cancer is the leading cancer among women in the United
States, with an estimated 266,120 new cases expected to be diagnosed
in 2018 (National Cancer Institute (NCI) Surveillance Epidemiology and
End Results (SEER), 2013). Established risk factors account for only a
fraction of the cases that occur (Cogliano et al., 2011; Madigan et al.,
1995). Increasing rates of breast cancer during the latter half of the last
century, coupled with the observation of elevated rates in industrialized
and urban areas, has led to speculation that environmental pollutants
may play a role in breast cancer etiology (Brody et al., 2007; Gray et al.,
2017; Salehi et al., 2008). Polybrominated diphenyl ethers (PBDEs) are
a family of synthetic brominated chemicals consisting of over 200
congeners. Introduced in the 1970s, PBDEs were added as flame re-
tardants to a variety of consumer products including polyurethane foam
cushioning in furniture and carpet padding, hard plastic casings in
appliances and electronics, and in upholstery and other household
textiles (Agency for Toxic Substances and Disease Registry (ATSDR),
2015; U.S. Environmental Protection Agency (EPA), 2017). After dec-
ades of widespread use, PBDEs have migrated from these products into
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the environment. Owing to their highly persistent and bioaccumulative
nature, they have become major persistent organic pollutants (POPs),
detected in nearly all environmental media tested, as well as in wildlife
and human tissue (Betts, 2008; Costa et al., 2008; Darnerud et al., 2001;
Environmental Working Group, 2007; Hites, 2004; Lorber, 2008;
United States Environmental Protection Agency, 2008; Sjodin et al.,
2008).
Interest in the PBDEs as potential human carcinogens stems from
their similar structure and toxicological properties to polychlorinated
biphenyls (PCBs), which are known human chemical carcinogens
(Betts, 2008; Lorber, 2008; McDonald, 2002; Siddiqi et al., 2003;
Lauby-Secretan et al., 2013). Moreover, interest in breast cancer, which
is a hormonally-mediated disease, has been driven by a substantial
body of laboratory evidence demonstrating endocrine-disrupting effects
of PBDEs, including the ability to alter in vivo circulating sex hormone
concentrations, enhance estrogenic-like cellular proliferation in MCF-7
cell lines, and interact with estrogen and androgen signaling pathways
(Costa et al., 2008; Darnerud, 2008; Gregoraszczuk et al., 2008; Hamers
et al., 2006; He et al., 2008; Meerts et al., 2001; Mercado-Feliciano and
Bigsby, 2008a, 2008b; Talsness, 2008; Talsness et al., 2008; Legler,
2008; Lyche et al., 2015; Karpeta and Gregoraszczuk, 2017; Karpeta
et al., 2016; Kwiecinska et al., 2011). None of the PBDEs have been
formally evaluated for carcinogenicity by the International Agency for
Research on Cancer. Only one PBDE congener (BDE-209) has been
evaluated by the United States Environmental Protection Agency (US
EPA), which classified it as a ‘suggestive’ human carcinogen in 2008
(U.S. Environmental Protection Agency, 2008). More recently, how-
ever, the US National Toxicology Program conducted a rodent bioassay
for a mixture of BDEs consisting of BDE-47, BDE-99 and BDE-153
(predominant congeners in what was once the most-commonly used
commercial BDE formulation) and concluded there was ‘clear evidence
of carcinogenicity’, primarily based on associations found with several
hepatic cancers in rodent models (U.S. Environmental Protection
Agency (EPA), 2017; US Department of Health and Human Services,
2015).
Human data are sparse. Only a handful of small case-control studies
have evaluated PBDEs and cancer risk. Increased risks have been re-
ported for testicular cancer (Hardell et al., 2006) and childhood acute
lymphoblastic leukemia (Ward et al., 2014). The epidemiologic evi-
dence for thyroid cancer is mixed, with one studying reporting no as-
sociation (Aschebrook-Kilfoy et al., 2015) while another reporting
elevated risks associated with BDE-209 measured in household dust
(Hoffman et al., 2017). Neither of the two small breast cancer studies
conducted to date found a significant association with PBDEs (Holmes
et al., 2014; Hurley et al., 2011).
The objective of the current study was to evaluate the risk of in-
vasive breast cancer associated with serum PBDE levels among 1838
women participating in a case-control study nested within the
California Teachers Study (CTS) cohort.
2. Materials and methods
2.1. Study population
The study participants were drawn from the CTS, an on-going pro-
spective cohort study of 133,479 female California public school pro-
fessionals initiated in 1995–1996 primarily to study breast cancer.
Details of the creation and conduct of the CTS are published elsewhere
(Bernstein et al., 2002). Briefly, since the CTS was established via re-
sponses to a mailed questionnaire, the cohort has been followed an-
nually for cancer diagnoses, deaths, and changes of address. State and
national mortality files, as well as reports from relatives, are used to
ascertain dates and causes of death. Address changes for continued
follow-up are obtained by several methods including annual mailings,
notifications of moves received from participants, and linkages to na-
tionwide consumer reporting companies and the U.S. Postal Service
National Change of Address database. Cancer outcomes are identified
through annual linkages with the California Cancer Registry (CCR), a
legally mandated statewide population-based cancer reporting system.
Case ascertainment for the CCR is estimated to be 99% complete and
99% of breast cancer tumors are pathologically confirmed (California
Cancer Registry (CCR) California Department of Health, 2017).
2.2. Case and control selection
Cases and controls included in the present analysis were drawn from
CTS members who had provided a blood sample and completed an
interview-administered questionnaire as part of their participation in a
separately-funded breast cancer case-control study nested within the
CTS cohort. Case selection criteria for the nested case-control study
included: diagnosis with invasive breast cancer (SEER Site
code=26,000) between January 1, 2006 and August 1, 2014 prior to
age 80 years; having no prior history of invasive or in situ breast cancer
when joining the cohort; and having lived continuously in California
from cohort entry until date of diagnosis with invasive breast cancer.
Controls were drawn from a probability sample of at-risk CTS cohort
members who had no diagnoses of invasive or in situ breast cancer and
were frequency matched to breast cancer cases by age at cohort entry
(5-year age groups), race/ethnicity and broad geographic region (cor-
responding to the three field study collection sites). Participation rates
were approximately 55% for controls and 65% for cases. Actively re-
fusing to participate was the most common reason for non-participation
(29% of controls, 21% of cases), followed by inability to contact (12%
for controls, 9% for cases). Approximately 4% of controls and 5% of
cases were excluded due to illness or death. Participants in the current
analyses were 902 invasive breast cancer cases and 936 controls who
participated in the larger CTS nested case-control study and who pro-
vided a blood specimen between November 2011 and August 2015 and
completed an interview-administered questionnaire at blood draw.
Blood specimens from cases were collected an average of 35months
after invasive breast cancer diagnosis (range of interval between diag-
nosis date and date of specimen collection was 9months to 8.5 years).
Informed consent was obtained from all individual participants in-
cluded in the study.
2.3. Serum collection
Non-fasting blood samples were collected, most frequently in par-
ticipants' homes, by licensed phlebotomists into a 10mL BD® tube
(catalog#367985, Becton Dickinson, Franklin Lakes, NJ) with clot ac-
tivator, double gel for transport, and silicone coated interior, using
standard phlebotomy techniques. Prior to field processing, specimens
were kept on cool packs for at least 30min. Within hours of collection,
phlebotomists separated the serum portion using portable centrifuges to
spin down the clotted blood samples. Processed samples were then
frozen and stored at −20 °C for 4–6 weeks until transported either via
local courier (on cool-packs) or overnight (on dry-ice via FedEx) to the
laboratory for chemical analysis. Samples remained frozen during this
transportation process. Upon receipt at the laboratory, specimens were
stored at −20 °C until analysis.
2.4. PBDE measurements
Serum samples were analyzed for 19 BDE congeners by the
Environmental Chemistry Laboratory at the California Department of
Toxic Substances Control (Berkeley, CA). Samples were thawed and
aliquoted for PBDE and lipid measurements. Automated solid phase
extraction (SPE; Biotage, Uppsala, Sweden) and gas chromatography/
high resolution mass spectrometry (GC-HRMS, DFS, ThermoFisher,
Bremen, Germany) were used for the analysis of PBDEs (Park et al.,
2015). Briefly, thawed serum samples (2mL) were fortified with a panel
of 13C12 labeled surrogate standards and mixed well. Equal volumes
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(4 mL) of formic acid and water were added into each sample before
loading on the SPE modules. Oasis HLB cartridges (3 cc, 500mg, Waters
Co., Milford, MA, USA) and acidified silica (500 °C pre-baked, manually
packed, 3 cc) were used for the sample extraction and clean-up, re-
spectively. The collected final eluates in hexane: dichlomethane (1:1)
were concentrated in TurboVap (Biotage, Charlotte, NC, USA), and
spiked with recovery standards. Standard reference material (SRM
1958, National Institute of Standards and Technology, Gaithersburg,
MD, USA) and bovine serum pre-spiked with known amounts of target
analytes were used as QA/QC samples. The laboratory is proficient in
the analysis of PBDEs as demonstrated by its regular participation in the
performance evaluation system managed by the Arctic Monitoring &
Assessment Program (AMAP). PBDE assays yielded concentrations re-
ported in ng/mL wet weight. A small volume of sera from each sample
was sent to Boston Children's Hospital for measurement of total cho-
lesterol and triglycerides by enzymatic methods (Allain et al., 1974;
Stinshoff et al., 1977). Cholesterol and triglycerides were used to cal-
culate total lipid content based on Phillips' formula (Phillips et al.,
1989). Detection frequencies varied widely by congener, ranging
from<1% for BDE-17 to approximately 87% for BDE-47 (Supple-
mental Table S1).
2.5. Covariate information
Information on potential covariates was derived from a series of
mailed surveys (a baseline questionnaire completed in 1995–1996 at
CTS enrollment and five follow-up surveys), as well as a survey ad-
ministered by an interviewer at the time of blood draw. Factors con-
sidered as potential covariates included established breast cancer risk
factors (based on a review of the literature) as well as factors that prior
exploratory analyses had identified as correlates to serum PBDE levels
in this study population. This initial set of potential covariates included
information on: demographics (age, race, neighborhood socioeconomic
status and urbanization); timing of blood draw (date and season of
blood collection); behavioral factors (smoking, alcohol consumption,
physical activity, use of menopausal hormone therapy (HT)); diet (total
fat, fiber, vitamin D, calories, red meat, pork, fish, and total meat
consumption); body mass index (BMI=weight in kg divided by square
of height in meters) and changes in body weight; family history of
breast cancer; and reproductive history (age at menarche, age at first
full term pregnancy, lactation history, menopausal status).
2.6. Statistical analysis
All analyses were conducted in SAS Version 9.04 (SAS Institute Inc.
and SAS Institute Inc., 2007). Statistical significance was defined at a p-
value<0.05. Concentrations below the LOD for which no signal was
detected were estimated by single imputation from a log-normal
probability distribution based on the observed distribution of quantified
measurements, following the method suggested by Lubin et al. (2004).
In order to minimize potential biases associated with imputing high
frequency of non-detectable levels, only the three congeners with de-
tection frequencies (DF) of 75% or more were included in our risk
analyses. These included: 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47),
2,2′,4,4′,6-pentabromodiphenyl ether (BDE-100), and 2,2′,4,4′,5,5′-
hexabromodiphenyl ether (BDE-153).
Prior to conducting the risk analyses, a number of exploratory and
descriptive analyses were conducted. Spearman rank correlation coef-
ficients (r) between BDE congeners were calculated. Because the con-
geners were highly correlated, we considered each PBDE separately in
our risk analyses.
The risk of breast cancer associated with each BDE congener was
estimated by unconditional logistic regression using PROC LOGISTIC to
generate odds ratios (OR) and 95% confidence intervals (95% CI).
These models were run on the measured and imputed wet weight values
(expressed as log10 [BDE, ng/mL]), adjusting for total serum lipid
content by the addition of a separate term in the model (expressed as
log10 [total lipids, ng/mL]), as recommended by Schisterman et al.
(2005). Smoothing splines were considered in generalized additive
models (using PROC GAM) and evaluated to assess potential non-line-
arities in the relationship between each PBDE and the log-odds of breast
cancer but no evidence of non-linearity was observed. In addition to
estimating breast cancer risks for the log-linear continuous values of
PBDE concentrations, we also estimated risks for quartiles of PBDE
concentrations based on the distribution among controls.
Minimally-adjusted crude ORs were generated from models that
included adjustment only for total serum lipids and the matching design
variables (age at enrollment, race/ethnicity, and study site). Fully-ad-
justed multivariable models were built via a two-step process. First, a
backwards elimination approach was used, starting with a model that
forced inclusion of the BDE variable, the matching design variables, and
serum lipid content and retention of covariates for which the p-value for
the Wald chi-square was<0.05. We then further evaluated potential
confounders by adding each of the excluded variables back into the
model one at a time and evaluated the change in the estimated OR for
the BDE variable. Factors that changed the estimated OR for the BDE by
≥10% were retained in our final multivariable models. While we
conducted this process separately for each BDE, it resulted in the same
set of covariates for all congeners. Final multivariable models included
terms for: age at baseline, race/ethnicity, study site, total serum lipid
content, date of blood draw, season of blood draw, BMI at baseline,
long-term moderate and strenuous physical activity, family history of
breast cancer, parity/age at first full term pregnancy, menopausal
status/HT use, and pork consumption at baseline (see Table 1 for details
of how these factors were specified in the models).
To evaluate whether risks differed within certain subsets of our
study population, a number of stratified analyses were conducted.
Subsets of interest were chosen a priori based on our review of the
literature. Selected subsets included: pre/peri-menopausal versus post-
menopausal women; cases with hormonally responsive tumors, identi-
fied as estrogen or progesterone receptor positive (ER+/PR+) versus
non-hormonally responsive tumors that were estrogen-receptor nega-
tive and progesterone-receptor negative (ER-/PR-); women who had
and had not ever used menopausal HT; women with low, medium and
high BMI; women who had and had not ever breastfed; women who
reported changes in body weight versus those with stable body weight
(≤5 pound change in body weight between enrollment in the study in
1995–1996 and the 2011–2012 mailed survey). Additionally, to explore
whether risks were confined to women who may have been exposed to
PBDEs during critical windows of susceptibility, we examined risks
among women who entered menopause or experienced their first full-
term pregnancy between 1990 and 2000 – the interval of time when
U.S. population PBDE exposures were likely at their peak (Guo et al.,
2016; Petreas et al., 2003; She et al., 2002; Sjodin et al., 2004). Due to
small numbers in some subsets, regression models for these analyses
were adjusted only for the matching design variables and total serum
lipids.
Two additional analyses were conducted to indirectly evaluate po-
tential biases that could have been introduced by the post-diagnostic
assessment of serum PBDE concentrations. These included: 1) evalu-
ating the Spearman Rank correlations between PBDE serum con-
centrations and the time interval between diagnosis and blood draw;
and 2) repeating our logistic regression analyses, stratified by the time
interval between diagnosis and blood draw (≤3 years and>3 years).
3. Results
Participants were predominantly middle-aged and older non-
Hispanic white women, reflecting the characteristics of the CTS cohort
from which they were selected. The median age of study participants at
CTS baseline enrollment was 49 years (range=24–71) and was
66 years (range= 41 to 87) at the time of blood collection for this
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study. Compared to controls, cases were significantly more likely to be
older and post-menopausal. Cases also were significantly more likely
than controls to report a family history of breast cancer, have higher
BMI, report less physical activity, and consume more pork. Controls
were significantly more likely than cases to have had their blood sample
collected during the initial few months of the study and during the fall
and winter months (Table 1). All factors as specified in Table 1 were
included as covariates in our logistic regression analyses.
Consistent with national biomonitoring data (Centers for Disease
Control and Prevention, 2015), lipid-normalized serum concentrations
were highest for BDE-47, followed by BDE-153, and BDE-100 (geo-
metric means=14.1 ng/g, 5.3 ng/g, and 2.6 ng/g, respectively). Sta-
tistically significant positive correlations (p < 0.001) were observed
between all congeners. Serum levels of BDE-100 and BDE-47 were
highly correlated (r=0.89) while BDE-153 was less strongly correlated
with the other congeners (r=0.54 for BDE-100; r=0.36 for BDE-47).
Serum PBDE and lipid concentrations for cases and controls are pre-
sented in Table 2. Median concentrations of the BDE congeners did not
statistically differ between cases and controls. Total Lipids were
Table 1
Distribution of selected characteristics for 1838 study participants.a,b
Characteristicb Case Control All
N Percent N Percent N Percent
All participants 902 100 936 100 1838 100
Age at baseline
questionnaire (years)c
24–39 113 13 204 22 317 17
40–44 121 13 141 15 262 14
45–49 206 23 174 19 380 21
50–54 195 22 177 19 372 20
55–59 152 17 129 14 281 15
60–71 115 13 111 12 226 12
Race/ethnicity
White 813 90 830 89 1643 89
Black 14 2 7 1 21 1
Hispanic 24 3 35 4 59 3
Asian/PI 29 3 36 4 65 4
Other 22 2 28 3 50 3
Study collection site
Cancer Prevention
Institute of California
437 48 467 50 904 49
City of Hope 277 31 282 30 559 31
University of California
Irvine
188 21 187 20 375 20
Family history of breast
cancer (first degree
relative)c
No 729 81 805 86 1534 83
Yes 136 15 102 11 238 13
Unknown 37 4 29 3 66 4
BMI (kg/m2) c
16.0–24.9 497 55 581 62 1078 59
25.0–29.9 236 26 213 23 449 24
30.0–54.8 153 17 117 13 270 15
Outlier/unknown 16 2 25 3 41 2
Long-term strenuous &
moderate physical
activity (hours/
week)c,d
≥4.00 275 30 312 33 587 32
0.50–3.99 257 28 311 33 568 31
<0.50 369 41 310 33 679 37
Unknown 1 0 3 0 4 0
Parity/age at first full-
term pregnancy
(years)
Nulliparous 234 26 226 24 460 25
≤24 years 206 23 246 26 452 25
25–29 years 259 29 269 29 528 29
≥30 years 193 21 180 19 373 20
Unknown 10 1 15 2 25 1
Dietary pork
consumptionc
None 354 39 413 44 767 42
<Median 243 27 279 30 522 28
≥Median 235 26 190 20 425 23
Unknown 70 8 54 6 124 7
Menopausal status/
hormone therapy
(HT) use at blood
drawc
Pre- or peri-menopausal 43 5 104 11 147 8
Post-menopausal and
never used HT
286 32 269 29 555 30
Post-menopausal and
ever used HT
573 64 562 60 1135 62
Unknown menopausal
status
0 0 1 0 1 0
Season of blood drawc
Winter 213 24 317 34 530 29
Spring 275 30 220 24 495 27
Summer 242 27 170 18 412 22
Fall 172 19 229 24 401 22
Date of blood drawc 902 Ave.: 5/
01/13
936 Ave.:6/
05/13
1838 Ave.: 5/
19/13
Table 1 (continued)
Characteristicb Case Control All
N Percent N Percent N Percent
Min:11/
22/11
Max: 8/
24/15
Min:11/
01/11
Max: 8/
24/15
Min: 1/
01/11
Max: 8/
24/15
a Includes all characteristics that were included as covariates in the fully-
adjusted multivariable logistic regression models.
b Characteristic assessed at CTS baseline enrollment, unless otherwise noted.
c Distributions for cases and controls were statistically different (i.e., p
(chisq) < 0.05).
d Long-term physical activity includes activity from high-school through
current age or age 54 if 55 years of age or older.
Table 2
Serum concentration of PBDEs and total lipids among 902 breast cancer cases
and 936 controls.a
DFd LODe Serum concentrationb,c
Mean Median Minimum Maximum p-Valuef
BDE-47
Cases 85.9 0.033 0.139 0.080 0.003 1.706
Controls 87.0 0.033 0.167 0.086 0.005 3.665 0.22
BDE-100
Cases 74.4 0.008 0.030 0.015 0.0003 0.873
Controls 76.4 0.008 0.034 0.016 0.001 0.841 0.39
BDE-153
Cases 75.5 0.017 0.074 0.030 0.001 2.233
Controls 78.0 0.017 0.080 0.032 0.001 2.905 0.54
Total lipids
Cases – – 6.43 6.26 3.86 12.62
Controls – – 6.54 6.46 3.18 11.48 0.01
a Data presented only for the BDE congeners with detection frequencies
(DF)≥75%.
b Concentration expressed in ng/mL for BDE congeners and mg/mL for total
lipids.
c Distributions for the BDE congeners based on measured and imputed values
where samples below the limit of detection (LOD) were estimated by single
imputation from a log-normal probability, based on method suggested by Lubin
et al. (2004).
d DF= detection frequency for BDE congener.
e LOD=average limit of detection for BDE congener.
f p-Value from the Wilcoxon rank sum test for differences in medians by case-
control status.
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marginally higher in controls compared to cases (p < 0.01), a differ-
ence that was driven by higher levels of cholesterol (median in con-
trols= 203.0mg/dL versus in cases= 194.0mg/dL, p < 0.01) but not
in triglycerides (median in controls= 112.0mg/dL versus in
cases= 115.0mg/dL, p=0.36)
The ORs for breast cancer associated with serum concentrations of
PBDEs from the crude and fully-adjusted multivariable logistic regres-
sions are presented in Table 3.
No statistically significant associations were observed for any of the
three congeners, regardless of whether the serum concentrations were
modeled as continuous or as ordinal terms. All ORs were close to 1.0
and 95% confidence intervals included 1.0. Estimates generated from
the crude and fully-adjusted models did not substantially differ.
Stratification of the data by menopausal status yielded risk estimates for
the post-menopausal women similar to those for the full study popu-
lation and no statistically significant effects were observed
(Supplemental Table S2). While the pattern of risk appeared somewhat
different among the small number of women (n=147) who were pre-
or peri-menopausal, none of the ORs significantly differed from one.
Likewise, stratification by tumor hormone responsiveness did not reveal
any statistically significant associations between PBDEs and breast
cancer risk (Supplemental Table S3). With few exceptions, stratification
by categories of BMI and changes in body weight generally yielded si-
milarly null results (Supplemental Tables S4 and S5). Analyses within
additional subsets of the study population (including parous women
who had breastfed, women who had never used menopausal hormone
therapy, and among women who entered menopause or experienced
their first full-term pregnancy during peak human population ex-
posures) demonstrated similar patterns of risk and did not yield sta-
tistically significant findings (data not shown).
Among the cases, we observed no evidence that serum PBDE con-
centrations varied by the time interval between diagnosis and blood
draw. There was no correlation between PBDE serum levels and the
time interval between diagnosis and blood draw (Spearman Rank cor-
relations ranged from −0.1 to 0.05 and none were statistically sig-
nificant). Moreover, stratified risk analyses indicated a similar pattern
of null results among both cases that had their blood drawn within
three years and those who had it drawn more than three years since
diagnosis.
4. Discussion
The results of this case-control study provide no evidence that
serum concentrations of BDE-47, BDE-100 or BDE-153 are associated
with breast cancer risk in this population of middle-aged and older
California women where cases' samples were collected several months
to several years after breast cancer diagnosis and treatment. All odds
ratio estimates were close to one with confidence intervals that in-
cluded one. While our subset analyses yielded a few statistically-sig-
nificant findings, these results were sensitive to whether the PBDE was
modeled as a continuous or an ordinal variable and showed no evidence
of dose-response. We therefore regard these few statistically significant
results as spurious findings, especially in light of the numerous subset
analyses that were conducted.
These results add to a small body of research on this topic. Only two
prior epidemiologic studies have evaluated the association between
body burden measurements of PBDEs and breast cancer risk, both of
which also reported null results (Holmes et al., 2014; Hurley et al.,
2011). One of these studies was conducted among women who were
demographically similar to those we studied–as it included women who
were mostly well-educated middle/upper-class non-Hispanic whites
living in the greater San Francisco Bay Area (SFBA) of California
(Hurley et al., 2011). The other study was conducted among Native
Alaskan women and reported a statistically significant unadjusted OR
for BDE-47 which did not persist after multivariable adjustment
(Holmes et al., 2014). These two prior case-control studies, each com-
prised of fewer than 80 cases, had limited statistical power to detect
risks. Furthermore, as hospital-based studies in which cases and con-
trols were both identified from pools of patients presenting for breast
surgeries (including biopsies, lumpectomies, mastectomies, or breast
reconstructions), these studies may have suffered from over-matching.
As the largest study conducted to date, our case-control study, nested
within a well-specified cohort, was better-positioned than prior studies
to explore associations between PBDEs and breast cancer risk. Never-
theless, several potential limitations are worth noting as they may have
impeded our ability to detect an association where one may have
Table 3
Association of invasive breast cancer risk with serum PBDE concentrations among 1838 study participants.
PBDE serum concentration # cases # controls Crudea,b
OR (95% CI)
p-Valuec Fully adjusteda,d
OR (95% CI)
p-Valuec
BDE-47
Q1 (lowest quartile) 240 237 1.00 (ref) 0.47 1.00 (ref) 0.28
Q2 234 231 1.03 (0.80, 1.34) 1.11 (0.85, 1.45)
Q3 218 234 0.93 (0.71, 1.21) 0.97 (0.74, 1.28)
Q4 (highest quartile) 210 234 0.93 (0.72, 1.22) 0.88 (0.67, 1.17)
log [BDE-47, ng/mL] 902 936 0.90 (0.72, 1.13) 0.37 0.84 (0.66, 1.07) 0.15
BDE-100
Q1 (lowest quartile) 240 231 1.00 (ref) 0.53 1.00 (ref) 0.29
Q2 231 237 0.95 (0.73, 1.23) 0.97 (0.75, 1.28)
Q3 212 233 0.89 (0.68, 1.15) 0.87 (0.66, 1.15)
Q4 (highest quartile) 219 235 0.94 (0.72, 1.22) 0.89 (0.67, 1.17)
log [BDE-100, ng/mL] 902 936 0.93 (0.76, 1.14) 0.48 0.87 (0.71, 1.08) 0.21
BDE-153
Q1 (lowest quartile) 232 227 1.00 (ref) 0.52 1.00 (ref) 0.65
Q2 236 240 1.03 (0.80, 1.34) 1.00 (0.77, 1.32)
Q3 240 235 1.09 (0.84, 1.41) 1.13 (0.86, 1.49)
Q4 (highest quartile) 194 234 0.89 (0.68, 1.17) 0.89 (0.67, 1.18)
log [BDE-153, ng/mL] 902 936 0.95 (0.78, 1.15) 0.57 0.93 (0.77, 1.14) 0.50
a OR=odds ratio; CI= confidence interval.
b Crude ORs adjusted for matching design variables of age at baseline enrollment, race/ethnicity, study collection site, and total serum lipids.
c For the categorical analysis, the p-values represent a test for linear trend with quartiles of PBDE modeled as a 4-level ordinal variable; for the continuous BDE
term, the p-value represents the p-value of the Wald-statistic for the b-coefficient for the BDE congener modeled as a continuous term.
d Fully adjusted ORs adjusted for age at baseline enrollment, race/ethnicity, study collection site, total serum lipids, date of blood draw, season of blood draw,
body mass index, physical activity, family history of breast cancer, parity/age at first full-term pregnancy, menopausal status/hormone therapy use at blood draw,
and pork consumption.
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existed.
The most important potential limitation to our study is that our
cases' PBDE measurements were from blood collected an average of
35months after diagnosis and after treatment. While it was not possible
to directly ascertain the degree to which this may have influenced our
results, our efforts to indirectly assess this issue through a number of
sensitivity analyses did not reveal any evidence that PBDE levels in
cases varied by how much time had elapsed between diagnosis and
blood sample collection. To our knowledge, no data have been pub-
lished on how PBDE serum levels may be affected by the onset of breast
cancer or influenced by its treatment. However, a few small exploratory
studies have evaluated this issue for other lipophilic POPs and these
may offer some insight. A breast cancer study that had serial measures
of organochlorine compounds in serum taken over the course of two-
years (including at least 6months prior to diagnosis in cases) reported
similar declines in cases and controls, suggesting that the onset of dis-
ease did not affect serum levels (Wolff et al., 2000a). That study how-
ever was not able to account for treatment. One study of PCB serum
levels (Gammon et al., 1996) and another of breast cancer risk (Gatto
et al., 2007) suggested that both levels and risk may be modified by
chemotherapy. While these studies highlight the potential importance
of treatment effects, this issue remains poorly understood and re-
presents an area worthy of future research. Unfortunately, we do have
not complete information on treatment for our study participants.
Cancer treatment data for the CTS, derived from the CCR, consists of
information on first course of treatment and therefore does not capture
all therapies provided by adjuvant care. It is noteworthy, however, that
the two prior breast cancer case-control studies, which were also null,
were both based on biospecimens collected before treatment (Holmes
et al., 2014; Hurley et al., 2011).
The use of a single serum measurement has generally been accepted
as a reasonable proxy for chronic exposure levels of other POP com-
pounds in healthy individuals, based on a number of analyses that have
shown strong intra-individual correlations between serial measure-
ments taken over time and a constancy of the relative exposure rankings
(i.e., high/medium/low) across individuals over time (Gammon et al.,
1997; Vo et al., 2008; Wolff et al., 2000b). The degree to which this
supposition extends to the PBDEs, which have shorter half-lives than
many of the legacy POPs, is not known. PBDE exposures, however, are
ubiquitous and on-going. Thus, while a single serum measurement later
in life, such as was used in this study, may not be a precise estimate of
exposure for an earlier more etiologically-relevant time period, it likely
provides a reasonable characterization of relative ranking among study
participants. There are, however, several additional caveats related to
this issue worth noting that may be especially germane to breast cancer
studies. In particular, intra-individual changes in POPs body burden
levels may vary substantially by lactation history and BMI (Vo et al.,
2008; Wolff et al., 2000b; Chevrier et al., 2000; Rogan, 1996; Sasamoto
et al., 2006; Sweeney et al., 2001; Wolff et al., 2005), which are also
recognized risk factors for breast cancer. In our study, lactation history
was not associated with PBDE levels and analyses limited to those who
had never breastfed did not yield results that differed substantially from
those based on all women (data not shown). BMI, however, was a sig-
nificant confounder and our BMI-stratified analyses suggested a re-
duced risk for BDE-47 only among obese women (Supplemental Table
S4). In light of the many subset analyses that were conducted, and given
that this finding was sensitive to whether BDE-47 was specified as an
ordinal or continuous term, we tend to regard it as spurious. It is pos-
sible however that it could be an artifact of the degree to which a single
serum measurement taken later in life (and after diagnosis among
cases) may differentially capture chronic exposures among women with
varying BMI. Alternatively, it is possible this finding is reflective of
toxicokinetic mechanisms that are influenced by body weight, percen-
tage of body fat, or type of body fat– a supposition supported by
compelling evidence summarized in a recent review of the role of
adipose tissue in modulating POPs toxicity (La Merrill et al., 2013).
In addition to BMI, changes in body weight also appear to be im-
portant determinants of serum POPs concentrations (Chevrier et al.,
2000; Sweeney et al., 2001; Wolff et al., 2005; La Merrill et al., 2013;
Verner et al., 2008; Wolff et al., 2007). This is of concern because
changes in body weight, particularly weight gain, are common among
breast cancer patients, especially among those who receive che-
motherapy (Makari-Judson et al., 2007; Vance et al., 2011). Our ability
to fully consider changes in BMI was limited by the availability of se-
rially-collected BMI data at relevant points in time. Specifically, we did
not have updated BMI information at the time of blood collection but
rather had to rely on BMI information collected in 2011–2012 (which
ranged from as much as 4 years prior to within a year after blood col-
lection). Based on these data (which would not necessarily capture
changes in body weight related to diagnosis or treatment), we generally
did not observe differences in PBDE risks among women who did and
did not have substantial changes in body weight (Supplemental Table
S5).
Beyond the concern of whether the use of a single serum measure-
ment adequately serves as a valid proxy for chronic PBDE exposures,
another concern is that earlier exposures during potentially important
windows of susceptibility may not have been captured (Gray et al.,
2017; Institute of Medicine of the National Academies, 2014; Mouly
and Toms, 2016; Rodgers et al., 2018). Our attempts to indirectly ad-
dress this issue by doing some focused analyses for participants who
may have had the greatest opportunity of exposure by virtue of having
been pregnant or undergone menopause during the peak windows of
population exposures did not prove illustrative (data not shown). If risks
are only posed by exposures during perinatal or pubertal development,
the vast majority of our participants would not have been at risk as 75%
were born before 1952 and all were born before 1972 – prior to the
widespread use of these chemicals.
5. Conclusion
In summary, the results from this study add to a small body of
epidemiologic evidence that suggests PBDE exposures captured at
middle age or older are not related to breast cancer risk. While our large
study had substantially greater statistical power to detect effects than
the prior two studies, it shares with those studies the primary limitation
of reliance upon biomarkers of exposure that may not provide adequate
estimates of chronic or early-life exposures. Furthermore, in our study
we could not consider a number of factors that may be important
modifiers of risks associated with these compounds, including poly-
morphisms in Cytochrome p450 genes and other factors such as body
fat that may affect endogenous estrogen levels.
Given the few epidemiologic studies conducted to date, none of
which have been able to adequately address these methodologic lim-
itations, it would be premature to conclude that PBDEs pose no risk for
breast cancer. Further laboratory and epidemiologic investigations that
can better address these outstanding issues are warranted given the
ubiquitous human exposures to these compounds that are expected to
persist for many decades.
Funding
This research was supported by funds provided by The Regents of
the University of California, California Breast Cancer Research
Program, Grant Number 16ZB-8501 and National Cancer Institute (NCI)
of the National Institutes of Health (NIH), Grant R01 CA77398. The
collection of cancer incidence data used in this study was supported by
the California Department of Public Health pursuant to California
Health and Safety Code Section 103885; Centers for Disease Control
and Prevention’s (CDC) National Program of Cancer Registries, under
cooperative agreement 5NU58DP006344; the National Cancer
Institute’s Surveillance, Epidemiology and End Results Program under
contract HHSN261201800032I awarded to the University of California,
S. Hurley, et al. Environment International 127 (2019) 412–419
417
San Francisco, contract HHSN261201800015I awarded to the
University of Southern California, and contract HHSN261201800009I
awarded to the Public Health Institute. The opinions, findings, and
conclusions herein are solely the responsibility of the authors and do
not necessarily represent the official views of the NIH, the California
Department of Toxic Substances Control, the California Department of
Public Health, the Regents of the University of California, or any of its
programs.
Declarations of interest
None.
Acknowledgements
We express our appreciation to all the participants in the California
Teachers Study and to the phlebotomists, the researchers, analysts and
staff who have contributed to the success of this research, including
Hyoung-Gee Baek, Christine Duffy, Weihong Guo, Suhash Harwani,
Megan Johnson, Minhthu Le, Sabrina Smith, Jane Sullivan-Halley,
Yunzhu Wang and the California Teachers Study Steering Committee
members who continue to work on other aspects of the CTS cohort,
including Jessica Clague deHart, Dennis Deapen, James V. Lacey Jr.,
Eunjung Lee, Huiyan Ma, Hannah Park, Richard Pinder, Sophia S.
Wang, and Argyrios Ziogas.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.envint.2019.03.043.
References
Agency for Toxic Substances and Disease Registry (ATSDR), 2015. Toxicological Profile
for Polybrominated Diphenyl Ether (draft for public comment). 2015. In: U.S.
Department of Health and Human Services Public Health Service, editor. Atlanta GA.
Allain, C.C., Poon, L.S., Chan, C.S., Richmond, W., Fu, P.C., 1974. Enzymatic determi-
nation of total serum cholesterol. Clin. Chem. 20 (4), 470–475.
Aschebrook-Kilfoy, B., DellaValle, C.T., Purdue, M., Kim, C., Zhang, Y., Sjodin, A., et al.,
2015. Polybrominated diphenyl ethers and thyroid cancer risk in the Prostate,
Colorectal, Lung, and Ovarian Cancer Screening Trial cohort. Am. J. Epidemiol. 181
(11), 883–888.
Bernstein, L., Allen, M., Anton-Culver, H., Deapen, D., Horn-Ross, P.L., Peel, D., et al.,
2002. High breast cancer incidence rates among California teachers: results from the
California Teachers Study (United States). Cancer Causes Control 13 (7), 625–635.
Betts, K.S., 2008. Unwelcome guest: PBDEs in indoor dust. Environ. Health Perspect. 116
(5), A202–A208.
Brody, J.G., Moysich, K.B., Humblet, O., Attfield, K.R., Beehler, G.P., Rudel, R.A., 2007.
Environmental pollutants and breast cancer: epidemiologic studies. Cancer. 109 (12
Suppl), 2667–2711.
California Cancer Registry (CCR) California Department of Health. California Cancer
Registry FAQ 2017 [Available from: http://www.ccrcal.org/Inside_CCR/FAQ.shtml.
Centers for Disease Control and Prevention. Fourth Report on Human Exposure to
Environmental Chemicals, Updated Tables, (February, 2015). Atlanta, GA; 2015.
Chevrier, J., Dewailly, E., Ayotte, P., Mauriege, P., Despres, J.P., Tremblay, A., 2000.
Body weight loss increases plasma and adipose tissue concentrations of potentially
toxic pollutants in obese individuals. Int. J. Obes. Relat. Metab. Disord. 24 (10),
1272–1278.
Cogliano, V.J., Baan, R., Straif, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., et al.,
2011. Preventable exposures associated with human cancers. J. Natl. Cancer Inst. 103
(24), 1827–1839.
Costa, L.G., Giordano, G., Tagliaferri, S., Caglieri, A., Mutti, A., 2008. Polybrominated
diphenyl ether (PBDE) flame retardants: environmental contamination, human body
burden and potential adverse health effects. Acta Biomed 79 (3), 172–183.
Darnerud, P.O., 2008. Brominated flame retardants as possible endocrine disrupters. Int.
J. Androl. 31 (2), 152–160.
Darnerud, P.O., Eriksen, G.S., Johannesson, T., Larsen, P.B., Viluksela, M., 2001.
Polybrominated diphenyl ethers: occurrence, dietary exposure, and toxicology.
Environ. Health Perspect. 109 (Suppl. 1), 49–68.
Environmental Working Group. In the dust. Toxic Fire Retardants in American Homes
Washington, D.C.: Environmental Working Group; 2007 [Available from: http://
www.ewg.org/node/8452.
Gammon, M.D., Wolff, M.S., Neugut, A.I., Terry, M.B., Britton, J.A., Greenebaum, E.,
et al., 1996. Treatment for breast cancer and blood levels of chlorinated hydro-
carbons. Cancer Epidemiol. Biomark. Prev. 5 (6), 467–471.
Gammon, M.D., Wolff, M.S., Neugut, A.I., Terry, M.B., Papadopoulos, K., Levin, B., et al.,
1997. Temporal variation in chlorinated hydrocarbons in healthy women. Cancer
Epidemiol. Biomark. Prev. 6 (5), 327–332.
Gatto, N.M., Longnecker, M.P., Press, M.F., Sullivan-Halley, J., McKean-Cowdin, R.,
Bernstein, L., 2007. Serum organochlorines and breast cancer: a case-control study
among African-American women. Cancer Causes Control 18 (1), 29–39.
Gray, J.M., Rasanayagam, S., Engel, C., Rizzo, J., 2017. State of the evidence 2017: an
update on the connection between breast cancer and the environment. Environ.
Health 16 (1), 94.
Gregoraszczuk, E.L., Rak, A., Kawalec, K., Ropstad, E., 2008. Steroid secretion following
exposure of ovarian follicular cells to single congeners and defined mixture of
polybrominateddibenzoethers (PBDEs), p,p'-DDT and its metabolite p,p'-DDE.
Toxicol. Lett. 178 (2), 103–109.
Guo, W., Holden, A., Smith, S.C., Gephart, R., Petreas, M., Park, J.S., 2016. PBDE levels in
breast milk are decreasing in California. Chemosphere. 150, 505–513.
Hamers, T., Kamstra, J.H., Sonneveld, E., Murk, A.J., Kester, M.H., Andersson, P.L., et al.,
2006. In vitro profiling of the endocrine-disrupting potency of brominated flame
retardants. Toxicol. Sci. 92 (1), 157–173.
Hardell, L., Bavel, B., Lindstrom, G., Eriksson, M., Carlberg, M., 2006. In utero exposure to
persistent organic pollutants in relation to testicular cancer risk. Int. J. Androl. 29 (1),
228–234.
He, Y., Murphy, M.B., Yu, R.M., Lam, M.H., Hecker, M., Giesy, J.P., et al., 2008. Effects of
20 PBDE metabolites on steroidogenesis in the H295R cell line. Toxicol. Lett. 176 (3),
230–238.
Hites, R.A., 2004. Polybrominated diphenyl ethers in the environment and in people: a
meta-analysis of concentrations. Environ. Sci. Technol. 38 (4), 945–956.
Hoffman, K., Lorenzo, A., Butt, C.M., Hammel, S.C., Henderson, B.B., Roman, S.A., et al.,
2017. Exposure to flame retardant chemicals and occurrence and severity of papillary
thyroid cancer: a case-control study. Environ. Int. 107, 235–242.
Holmes, A.K., Koller, K.R., Kieszak, S.M., Sjodin, A., Calafat, A.M., Sacco, F.D., et al.,
2014. Case-control study of breast cancer and exposure to synthetic environmental
chemicals among Alaska Native women. Int. J. Circumpolar Health 73 (1), 25760.
Hurley, S., Reynolds, P., Goldberg, D., Nelson, D.O., Jeffrey, S.S., Petreas, M., 2011.
Adipose levels of polybrominated diphenyl ethers and risk of breast cancer. Breast
Cancer Res. Treat. 129 (2), 505–511.
Institute of Medicine of the National Academies, 2012. Breast Cancer and the
Environment: A Life Course Approach. The National Academies Press,
Washington, D.C.
Karpeta, A., Gregoraszczuk, E.L., 2017. Differences in the mechanisms of action of BDE-47
and its metabolites on OVCAR-3 and MCF-7 cell apoptosis. J. Appl. Toxicol. 37 (4),
426–435.
Karpeta, A., Maniecka, A., Gregoraszczuk, E.L., 2016. Different mechanisms of action of 2,
2′, 4, 4′-tetrabromodiphenyl ether (BDE-47) and its metabolites (5-OH-BDE-47 and 6-
OH-BDE-47) on cell proliferation in OVCAR-3 ovarian cancer cells and MCF-7 breast
cancer cells. J. Appl. Toxicol. 36 (12), 1558–1567.
Kwiecinska, P., Wrobel, A., Gregoraszczuk, E.L., 2011. Combinatory effects of PBDEs and
17beta-estradiol on MCF-7 cell proliferation and apoptosis. Pharmacol. Rep. 63 (1),
189–194.
La Merrill, M., Emond, C., Kim, M.J., Antignac, J.P., Le Bizec, B., Clement, K., et al., 2013.
Toxicological function of adipose tissue: focus on persistent organic pollutants.
Environ. Health Perspect. 121 (2), 162–169.
Lauby-Secretan, B., Loomis, D., Grosse, Y., El Ghissassi, F., Bouvard, V., Benbrahim-
Tallaa, L., et al., 2013. Carcinogenicity of polychlorinated biphenyls and poly-
brominated biphenyls. Lancet Oncol. 14 (4), 287–288.
Legler, J., 2008. New insights into the endocrine disrupting effects of brominated flame
retardants. Chemosphere. 73 (2), 216–222.
Lorber, M., 2008. Exposure of Americans to polybrominated diphenyl ethers. J. Expo. Sci.
Environ. Epidemiol. 18 (1), 2–19.
Lubin, J.H., Colt, J.S., Camann, D., Davis, S., Cerhan, J.R., Severson, R.K., et al., 2004.
Epidemiologic evaluation of measurement data in the presence of detection limits.
Environ. Health Perspect. 112 (17), 1691–1696.
Lyche, J.L., Rosseland, C., Berge, G., Polder, A., 2015. Human health risk associated with
brominated flame-retardants (BFRs). Environ. Int. 74, 170–180.
Madigan, M.P., Ziegler, R.G., Benichou, J., Byrne, C., Hoover, R.N., 1995. Proportion of
breast cancer cases in the United States explained by well-established risk factors. J.
Natl. Cancer Inst. 87 (22), 1681–1685.
Makari-Judson, G., Judson, C.H., Mertens, W.C., 2007. Longitudinal patterns of weight
gain after breast cancer diagnosis: observations beyond the first year. Breast J. 13 (3),
258–265.
McDonald, T.A., 2002. A perspective on the potential health risks of PBDEs.
Chemosphere. 46 (5), 745–755.
Meerts, I.A., Letcher, R.J., Hoving, S., Marsh, G., Bergman, A., Lemmen, J.G., et al., 2001.
In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and
polybrominated bisphenol A compounds. Environ. Health Perspect. 109 (4),
399–407.
Mercado-Feliciano, M., Bigsby, R.M., 2008a. Hydroxylated metabolites of the poly-
brominated diphenyl ether mixture DE-71 are weak estrogen receptor-alpha ligands.
Environ. Health Perspect. 116 (10), 1315–1321.
Mercado-Feliciano, M., Bigsby, R.M., 2008b. The polybrominated diphenyl ether mixture
DE-71 is mildly estrogenic. Environ. Health Perspect. 116 (5), 605–611.
Mouly, T.A., Toms, L.L., 2016. Breast cancer and persistent organic pollutants (excluding
DDT): a systematic literature review. Environ. Sci. Pollut. Res. Int. 23 (22),
22385–22407.
National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER)
Cancer Stat Facts: Common Cancer Sites: National Cancer Institute (NCI)
Surveillance, Epidemiology and End Results (SEER) 2013 [Available from: https://
S. Hurley, et al. Environment International 127 (2019) 412–419
418
seer.cancer.gov/statfacts/html/common.html.
Park, J.S., Voss, R.W., McNeel, S., Wu, N., Guo, T., Wang, Y., et al., 2015. High exposure
of California firefighters to polybrominated diphenyl ethers. Environ. Sci. Technol. 49
(5), 2948–2958.
Petreas, M., She, J., Brown, F.R., Winkler, J., Windham, G., Rogers, E., et al., 2003. High
body burdens of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) in California women.
Environ. Health Perspect. 111 (9), 1175–1179.
Phillips, D.P.J., Burse, V., Bernert Jr., J., Henderson, L., Needham, L., 1989. Chlorinated
hydrocarbon levels in human serum: effects of fasting and feeding. Arch. Environ.
Contam. Toxicol. 18 (4), 495–500.
Rodgers, K.M., Udesky, J.O., Rudel, R.A., Brody, J.G., 2018. Environmental chemicals and
breast cancer: an updated review of epidemiological literature informed by biological
mechanisms. Environ. Res. 160, 152–182.
Rogan, W.J., 1996. Pollutants in breast milk. Arch. Pediatr. Adolesc. Med. 150 (9),
981–990.
Salehi, F., Turner, M.C., Phillips, K.P., Wigle, D.T., Krewski, D., Aronson, K.J., 2008.
Review of the etiology of breast cancer with special attention to organochlorines as
potential endocrine disruptors. J. Toxicol. Environ. Health B Crit. Rev. 11 (3–4),
276–300.
SAS Institute Inc. SAS 11.0. 9 ed. Cary, NC: SAS Institute Inc.; 2007.
Sasamoto, T., Horii, S., Ibe, A., Takada, N., Shirota, K., 2006. Concentration changes of
PCDDs, PCDFs, and dioxin-like PCBs in human breast milk samples as shown by a
follow-up survey. Chemosphere. 64 (4), 642–649.
Schisterman, E.F., Whitcomb, B.W., Louis, G.M., Louis, T.A., 2005. Lipid adjustment in
the analysis of environmental contaminants and human health risks. Environ. Health
Perspect. 113 (7), 853–857.
She, J., Petreas, M., Winkler, J., Visita, P., McKinney, M., Kopec, D., 2002. PBDEs in the
San Francisco Bay Area: measurements in harbor seal blubber and human breast
adipose tissue. Chemosphere. 46 (5), 697–707.
Siddiqi, M.A., Laessig, R.H., Reed, K.D., 2003. Polybrominated diphenyl ethers (PBDEs):
new pollutants-old diseases. Clin. Med. Res. 1 (4), 281–290.
Sjodin, A., Jones, R.S., Focant, J.F., Lapeza, C., Wang, R.Y., McGahee 3rd, E.E., et al.,
2004. Retrospective time-trend study of polybrominated diphenyl ether and poly-
brominated and polychlorinated biphenyl levels in human serum from the United
States. Environ. Health Perspect. 112 (6), 654–658.
Sjodin, A., Wong, L.Y., Jones, R.S., Park, A., Zhang, Y., Hodge, C., et al., 2008. Serum
concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated bi-
phenyl (PBB) in the United States population: 2003-2004. Environ. Sci. Technol. 42
(4), 1377–1384.
Stinshoff, K., Weisshaar, D., Staehler, F., Hesse, D., Gruber, W., Steier, E., 1977. Relation
between concentrations of free glycerol and triglycerides in human sera. Clin. Chem.
23 (6), 1029–1032.
Sweeney, A.M., Symanski, E., Burau, K.D., Kim, Y.J., Humphrey, H.E., Smithci, M.A.,
2001. Changes in serum PBB and PCB levels over time among women of varying ages
at exposure. Environ. Res. 86 (2), 128–139.
Talsness, C.E., 2008. Overview of toxicological aspects of polybrominated diphenyl
ethers: a flame-retardant additive in several consumer products. Environ. Res. 108
(2), 158–167.
Talsness, C.E., Kuriyama, S.N., Sterner-Kock, A., Schnitker, P., Grande, S.W., Shakibaei,
M., et al., 2008. In utero and lactational exposures to low doses of polybrominated
diphenyl ether-47 alter the reproductive system and thyroid gland of female rat
offspring. Environ. Health Perspect. 116 (3), 308–314.
U.S. Environmental Protection Agency. Toxicological review of decabromodiphenyl ether
(BDE-209). In Support of Summary Information on the Integrated Risk Information
System (IRIS) Washington, D.C.June 2008 [Available from: https://cfpub.epa.gov/
ncea/iris/search/index.cfm?keyword=BDE-209.
U.S. Environmental Protection Agency (EPA). Technical fact sheet - polybrominated di-
phenyl ethers (PBDEs), EPA 505-F-17-015 2017 [cited 2018. Available from: https://
www.epa.gov/sites/production/files/2014-03/documents/ffrrofactsheet_
contaminant_perchlorate_january2014_final_0.pdf.
United States Environmental Protection Agency, 2008. Emerging contaminants – poly-
brominated diphenyl ethers (PBDE) and polybrominated biphenyls (PBB) fact sheet.
In: Solid Waste and Emergency Response, editor.
US Department of Health and Human Services. DRAFT: NTP Technical Report on the the
Toxiciology of A Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] 2015
Available from: https://ntp.niehs.nih.gov/ntp/about_ntp/trpanel/2015/june/tr589_
peerdraft.pdf.
Vance, V., Mourtzakis, M., McCargar, L., Hanning, R., 2011. Weight gain in breast cancer
survivors: prevalence, pattern and health consequences. Obes. Rev. 12 (4), 282–294.
Verner, M.A., Charbonneau, M., Lopez-Carrillo, L., Haddad, S., 2008. Physiologically
based pharmacokinetic modeling of persistent organic pollutants for lifetime ex-
posure assessment: a new tool in breast cancer epidemiologic studies. Environ. Health
Perspect. 116 (7), 886–892.
Vo, T.T., Gladen, B.C., Cooper, G.S., Baird, D.D., Daniels, J.L., Gammon, M.D., et al.,
2008. Dichlorodiphenyldichloroethane and polychlorinated biphenyls: in-
traindividual changes, correlations, and predictors in healthy women from the
southeastern United States. Cancer Epidemiol. Biomark. Prev. 17 (10), 2729–2736.
Ward, M.H., Colt, J.S., Deziel, N.C., Whitehead, T.P., Reynolds, P., Gunier, R.B., et al.,
2014. Residential levels of polybrominated diphenyl ethers and risk of childhood
acute lymphoblastic leukemia in California. Environ. Health Perspect. 122 (10),
1110–1116.
Wolff, M.S., Berkowitz, G.S., Brower, S., Senie, R., Bleiweiss, I.J., Tartter, P., et al., 2000a.
Organochlorine exposures and breast cancer risk in New York City women. Environ.
Res. 84 (2), 151–161.
Wolff, M.S., Zeleniuch-Jacquotte, A., Dubin, N., Toniolo, P., 2000b. Risk of breast cancer
and organochlorine exposure. Cancer Epidemiol. Biomark. Prev. 9 (3), 271–277.
Wolff, M.S., Britton, J.A., Teitelbaum, S.L., Eng, S., Deych, E., Ireland, K., et al., 2005.
Improving organochlorine biomarker models for cancer research. Cancer Epidemiol.
Biomark. Prev. 14 (9), 2224–2236.
Wolff, M.S., Anderson, H.A., Britton, J.A., Rothman, N., 2007. Pharmacokinetic varia-
bility and modern epidemiology–the example of dichlorodiphenyltrichloroethane,
body mass index, and birth cohort. Cancer Epidemiol. Biomark. Prev. 16 (10),
1925–1930.
S. Hurley, et al. Environment International 127 (2019) 412–419
419
